COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #67 of 230
6/22 Late treatment study
Fontana et al., Clinical Kidney Journal, 13:3, 334–339, doi:10.1093/ckj/sfaa084 (Peer Reviewed)
SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience
Source   PDF   Share   Tweet
Very small observational study of 15 dialysis patients showing HCQ mortality RR 0.50, p = 0.53.

Fontana et al., 6/22/2020, retrospective, Italy, Europe, peer-reviewed, 8 authors.
risk of death, 50.0% lower, RR 0.50, p = 0.53, treatment 4 of 12 (33.3%), control 2 of 3 (66.7%).
Details of all 230 studies    Meta analysis
Please submit corrections, updates, or comments.
Submit